Article
Cell Biology
Yujing Li, Yifan Sun, Michael Kulke, Torsten Hechler, Kevin Van der Jeught, Tianhan Dong, Bin He, Kathy D. Miller, Milan Radovich, Bryan P. Schneider, Andreas Pahl, Xinna Zhang, Xiongbin Lu
Summary: The heterozygous loss of chromosome 17p, a common genomic event in breast cancer, leads to global gene expression changes, reduced T cell tumor infiltration, and deletion of tumor suppressor genes like TP53. This loss also makes breast cancer cells sensitive to POLR2A inhibition, enabling targeted precision immunotherapy.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Review
Engineering, Biomedical
Janske Nel, Kamil Elkhoury, Emilie Velot, Arnaud Bianchi, Samir Acherar, Gregory Francius, Ali Tamayol, Stephanie Grandemange, Elmira Arab-Tehrany
Summary: Despite progress in breast cancer research, it remains a leading cause of female mortality globally. Chemotherapies have limitations, such as lack of specificity and multi-drug resistance. Liposomes as drug delivery systems have potential, but few are clinically approved and none have active targeting. This review summarizes recent developments in actively targeted liposomal drug delivery systems for breast cancer.
BIOACTIVE MATERIALS
(2023)
Article
Oncology
Celia Nieto, Milena A. Vega, Eva Martin del Valle
Summary: Novel nanoparticles loaded with paclitaxel and trastuzumab showed more remarkable antitumor activity and lower toxicity to normal tissues than previous nanosystems, offering a promising strategy to improve current HER2-positive breast cancer therapies.
Article
Oncology
Josee-Lyne Ethier, Danielle Desautels, Andrew Robinson, Eitan Amir, Weidong Kong, Christopher M. Booth
Summary: This study examined the use of pertuzumab and T-DM1 in routine clinical practice in Ontario, Canada. The survival outcomes of patients treated with pertuzumab and T-DM1 in routine practice appeared to be inferior to results from pivotal clinical trials. Further research is needed to understand the effectiveness of T-DM1 after pertuzumab exposure.
Article
Medicine, Research & Experimental
Myrto Moutafi, Charles J. Robbins, Vesal Yaghoobi, Aileen Fernandez, Sandra Martinez-Morilla, Vasiliki Xirou, Yalai Bai, Yan Song, Patricia Gaule, Joseph Krueger, Kenneth Bloom, Salisha Hill, Daniel C. Liebler, Regan Fulton, David L. Rimm
Summary: The efficacy of the antibody drug conjugate Trastuzumab deruxtecan (T-DXd) in HER2 low breast cancer patients suggests the need for revision of the conventional HER2 assays. In this study, an optimized dynamic range for unamplified HER2 detection in breast cancer was determined and a quantitative assay to stratify HER2 expression in unamplified cases was designed. The application of this assay to a large number of breast cancer cases demonstrated its potential for selecting optimal patients for T-DXd treatment.
LABORATORY INVESTIGATION
(2022)
Article
Medicine, Research & Experimental
Dorota Bartusik-Aebisher, Grzegorz Chrzanowski, Zuzanna Bober, David Aebisher
Summary: This study aimed to investigate the Trastuzumab-dendrimer-fluorine drug delivery system by synthesizing and characterizing a series of fluorinated dendrimers. The results from electrophoresis, HPLC, and LC-MS techniques showed the potential and efficiency of the synthesized drug delivery system. Three-dimensional cell culture experiments and MRI measurements confirmed the efficacy of the novel system in treating breast cancer cells with Her-2 overexpression.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Nanoscience & Nanotechnology
Yan Tan, Yingying Li, Yi-Xin Qu, Yuanye Su, Yongbo Peng, Zilong Zhao, Ting Fu, Xue-Qiang Wang, Weihong Tan
Summary: The study discusses the design and development of anti-MUC1 aptamer-peptide conjugates as targeted chemosensitizers to overcome issues related to high levels of HSP70 in tumors. This innovative conjugate not only enhances the sensitivity of DOX-resistant cells but also alleviates DOX-induced cardiotoxicity, highlighting the success of this targeted chemosensitizer strategy.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Review
Oncology
Xiaolu Sun, Kuai Liu, Shuli Lu, Weina He, Zixiu Du
Summary: Breast cancer is a molecularly diverse disease with heterogeneity. Targeted therapy and immunotherapy offer solutions to improve prognosis and address drug resistance. Molecular classifications are important for clinical diagnosis and treatment strategies differ according to the molecular subtype. Targeted therapy and immunotherapy provide hope for the treatment of breast cancer.
Article
Pharmacology & Pharmacy
Zimiao Luo, Sunyi Wu, Jianfen Zhou, Weixia Xu, Qianzhu Xu, Linwei Lu, Cao Xie, Yu Liu, Weiyue Lu
Summary: Brain metastasis is a common and serious complication of breast cancer, especially in triple-negative breast cancer (TNBC). This study develops a Y-shaped peptide pVAP-decorated platelet-hybrid liposome drug delivery system to achieve targeted drug delivery for the treatment of brain metastasis from TNBC. The results show that this delivery platform significantly improves drug accumulation and exhibits superior inhibition of brain metastasis compared to the free drug. This work provides a promising prospect for the comprehensive treatment of brain metastasis in TNBC.
ACTA PHARMACEUTICA SINICA B
(2023)
Article
Engineering, Biomedical
Kwang Suk Lim, Daniel Y. Lee, Seungmin Han, David A. Bull, Young-Wook Won
Summary: HSP90 is crucial for cancer cell survival, and incorporating HSP90 inhibitors into antibodies through biological affinity binding can enhance targeted delivery and improve anti-cancer efficacy.
Review
Chemistry, Multidisciplinary
Yu Han, Panyue Wen, Junjie Li, Kazunori Kataoka
Summary: Cisplatin is a successful chemotherapy drug, but its resistance and toxicity limit its clinical application. Targeted nanomedicine offers hope for maximizing efficacy and minimizing toxicity. This article reviews the recent progress and challenges in managing cisplatin resistance and toxicity and highlights future directions for development.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Pharmacology & Pharmacy
Mirina Sakhi, Abad Khan, Zafar Iqbal, Ismail Khan, Abida Raza, Asmat Ullah, Fazli Nasir, Saeed Ahmad Khan
Summary: The aim of this study was to develop an antibody-mediated drug delivery system for the treatment of breast cancer. The results showed that the antibody-conjugated polymeric nanoparticles exhibited controlled and sustained drug release, improved cytotoxicity, and enhanced pharmacokinetic parameters compared to conventional nanoparticles and commercially available formulations.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Marta Sevieri, Serena Mazzucchelli, Linda Barbieri, Stefania Garbujo, Stephana Carelli, Arianna Bonizzi, Federica Rey, Camilla Recordati, Matteo Recchia, Raffaele Allevi, Leopoldo Sitia, Carlo Morasso, Pietro Zerbi, Davide Prosperi, Fabio Corsi, Marta Truffi
Summary: The study demonstrates the potential of a nanoconjugate called H-TZ, consisting of TZ and HFn, in delivering TZ to the brain and combating HER2+ breast cancer brain metastasis. H-TZ efficiently reduces tumor growth, avoids cardiotoxicity, and shows promise for managing BC metastatic to the brain.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Medicine, Research & Experimental
Malcolm Lim, Nicholas L. Fletcher, Jodi M. Saunus, Amy E. McCart Reed, Haarika Chittoory, Peter T. Simpson, Kristofer J. Thurecht, Sunil R. Lakhani
Summary: This study demonstrates the potential of a HER3-targeted hyperbranched polymer (HBP) nanomedicine for the treatment of breast cancer brain metastases. The HBP carrier can selectively deliver and release the chemotherapy drug doxorubicin (DOX) in a pH-responsive manner. The nanomedicine shows effective drug release and cytotoxicity against breast cancer cells, and in a mouse model, it inhibits tumor proliferation, reduces tumor size, and prolongs overall survival. Furthermore, the nanomedicine exhibits lower toxicity compared to free DOX.
MOLECULAR PHARMACEUTICS
(2023)
Article
Medicine, Research & Experimental
Xiangjun Chen, Mingyi Hou, Xinzhong Zhang, Haixin Liu, Wenting Li, Wei Hong
Summary: Nanoscale structures have been developed for various functions in cancer therapy, including diagnosis, biomedical visualization, tissue regeneration, and drug delivery. By using biocompatible chitosan oligosaccharides and gold nanorods, a drug delivery system was designed that effectively delivered drugs to tumor sites and selectively targeted cancer cells. The system also had drug release capability and magnetic resonance imaging functionality, showing promising outcomes for tumor diagnosis and treatment.
MOLECULAR PHARMACEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Shamma S. Rahman, Alexandra E. J. Moffitt, Andrew J. Trease, Kirk W. Foster, Matthew D. Storck, Hamid Band, Erika I. Boesen
Article
Biochemistry & Molecular Biology
Scott A. Nadeau, Wei An, Bhopal C. Mohapatra, Insha Mushtaq, Timothy A. Bielecki, Haitao Luan, Neha Zutshi, Gulzar Ahmad, Matthew D. Storck, Masashi Sanada, Seishi Ogawa, Vimla Band, Hamid Band
JOURNAL OF BIOLOGICAL CHEMISTRY
(2017)
Article
Immunology
Fany M. Iseka, Benjamin T. Goetz, Insha Mushtaq, Wei An, Luke R. Cypher, Timothy A. Bielecki, Eric C. Tom, Priyanka Arya, Sohinee Bhattacharyya, Matthew D. Storck, Craig L. Semerad, James E. Talmadge, R. Lee Mosley, Vimla Band, Hamid Band
JOURNAL OF IMMUNOLOGY
(2018)
Article
Spectroscopy
Xi Huang, Ye Yuan, Timothy A. Bielecki, Bhopal C. Mohapatra, Haitao Luan, Edibaldo Silva-Lopez, William W. West, Vimla Band, Yongfeng Lu, Hamid Band, Tian C. Zhang
JOURNAL OF RAMAN SPECTROSCOPY
(2017)
Article
Oncology
Haitao Luan, Bhopal Mohapatra, Timothy A. Bielecki, Insha Mushtaq, Sameer Mirza, Tameka A. Jennings, Robert J. Clubb, Wei An, Dena Ahmed, Rokaya El-Ansari, Matthew D. Storck, Nitish K. Mishra, Chittibabu Guda, Yuri M. Sheinin, Jane L. Meza, Srikumar Raja, Emad A. Rakha, Vimla Band, Hamid Band
Article
Biochemistry & Molecular Biology
Bennett H. Penn, Zoe Netter, Jeffrey R. Johnson, John Von Dollen, Gwendolyn M. Jang, Tasha Johnson, Yamini M. Ohol, Cyrus Maher, Samantha L. Bell, Kristina Geiger, Guillaume Golovkine, Xiaotang Du, Alex Choi, Trevor Parry, Bhopal C. Mohapatra, Matthew D. Storck, Hamid Band, Chen Chen, Stefanie Jager, Michael Shales, Dan A. Portnoy, Ryan Hernandez, Laurent Coscoy, Jeffery S. Cox, Nevan J. Krogan
Correction
Developmental Biology
Bhopal Mohapatra, Neha Zutshi, Wei An, Benjamin Goetz, Priyanka Arya, Timothy A. Bielecki, Insha Mushtaq, Matthew D. Storck, Jane L. Meza, Vimla Band, Hamid Band
Article
Radiology, Nuclear Medicine & Medical Imaging
Nicholas E. Wojtynek, Madeline T. Olson, Timothy A. Bielecki, Wei An, Aaqib M. Bhat, Hamid Band, Scott R. Lauer, Edibaldo Silva-Lopez, Aaron M. Mohs
MOLECULAR IMAGING AND BIOLOGY
(2020)
Article
Oncology
Bhopal C. Mohapatra, Sameer Mirza, Aditya Bele, Channabasavaiah B. Gurumurthy, Mohsin Raza, Irfana Saleem, Matthew D. Storck, Aniruddha Sarkar, Sai Sundeep Kollala, Surendra K. Shukla, Siddesh Southekal, Kay-Uwe Wagner, Fang Qiu, Subodh M. Lele, Mansour A. Alsaleem, Emad A. Rakha, Chittibabu Guda, Pankaj K. Singh, Robert D. Cardiff, Hamid Band, Vimla Band
Summary: Ecdysoneless (ECD) protein is overexpressed in breast cancer and its overexpression predicts shorter survival in patients. In a mouse study, inducible overexpression of ECD led to mammary hyperplasia, pre-neoplastic lesions, heterogeneous tumors, and lung metastasis. ECD overexpression promoted epithelial to mesenchymal transition and cancer stem cell characteristics, and its oncogenic effects were mediated through regulation of c-MYC-mediated glucose metabolism.
MOLECULAR CANCER RESEARCH
(2022)
Article
Biology
Haitao Luan, Timothy A. Bielecki, Bhopal C. Mohapatra, Namista Islam, Insha Mushtaq, Aaqib M. Bhat, Sameer Mirza, Sukanya Chakraborty, Mohsin Raza, Matthew D. Storck, Michael S. Toss, Jane L. Meza, Wallace B. Thoreson, Donald W. Coulter, Emad A. Rakha, Vimla Band, Hamid Band
Summary: Understanding the cellular adaptations that promote metastasis in cancer could lead to new therapeutic targets. In this study, overexpression of EHD2 protein was found in breast cancers, particularly in the triple-negative and HER2+ subtypes, and correlated with shorter patient survival. EHD2 was linked to the stability of caveolae and the store-operated calcium entry (SOCE) pathway, promoting tumorigenesis and metastasis in breast cancer. Targeting the EHD2-SOCE axis may have potential therapeutic implications for breast cancer patients with EHD2 and CAV1/2 overexpression.
Article
Developmental Biology
Bhopal Mohapatra, Neha Zutshi, Wei An, Benjamin Goetz, Priyanka Arya, Timothy A. Bielecki, Insha Mustaq, Matthew D. Storck, Jane L. Meza, Vimla Band, Hamid Band